Overview

Efficacy and Immune Function of Pirfenidone in CTD-ILD

Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
A single-center randomized controlled study was used to observe the efficacy and immune function with/wo pirfenidone on CTD-ILD patients in QIlu Hospital of Shanndong University for 24 months. The main research endpoints are lung function ,patient dyspnea score,imaging indicators and so on.
Phase:
Phase 4
Details
Lead Sponsor:
Qilu Hospital of Shandong University
Treatments:
Glucocorticoids
Immunosuppressive Agents
Pirfenidone